

POST-OPERATIVE NAUSEA & VOMITING



Post-operative nausea and vomiting (PONV) is a **common complication after anesthesia** with an incidence from **33-82% following surgery** in pediatric patients.

PRESENTATION

Symptoms may begin in the post-anesthetic care unit within 6hrs (early onset), or > 6hrs and post discharge (late onset).

- Nausea
- Retching
- Vomiting
- Abdominal discomfort
- Pallor
- Diaphoresis

PATHOPHYSIOLOGY

Complex interactions between:

- Drugs (anesthetic gas, opioids)
- Central nervous system (fear, pain, vestibular system stimulation)
- Peripheral agents (gastric stimulation via blood or trauma)

These impact the nucleus tractus solitarius which release the following that contribute to nausea and vomiting:

- Histamine or muscarine
- Neurotransmitters (serotonin, dopamine, and neurokinin)

RISK FACTORS			
Pre-operative ≥ 3 years old Hx PONV Hx motion sickness FHx PONV Post pubertal female	Intra-operative Strabismus surgery Adeno- tonsillectomy & otoplasty ≥ 30 minutes of anesthesia gas Volatile gas Anti- cholinesterases	Post- operative Long acting opioids	

Eberhart Peds PONV		
Factor		Points
Age ≥ 3 years old		1
Surgery ≥ 30 Minutes		1
Strabismus Surgery		1
History PONV		1
Low Risk,	Moderate	High Risk,

Low Risk,	Moderate
≤ 1: Single	Risk, 2: Dual
agent	agent
prophylaxis	prophylaxis

High Risk, ≥3: Multi agent prophylaxis

PROPHYLAXIS

Low Risk

Consider adding ondansetron (5HT3 antagonist) OR dexamethasone

Moderate Risk

Ondansetron + Dexamethasone (any child >2yo getting general anesthetics)

High Risk

Ondansetron + Dexamethasone +/- total intravenous anesthetic (TIVA) +/- NK1 receptor antagonist (aprepitant)

Consider opioid sparing techniques including but not limited to **peripheral nerve blocks** & liberal fluid therapy. If there are multiple risk factors, consider a TIVA and/or aprepitant pre-op if prior strategies failed.

TREATMENT OF ACUTE PONV

If no prophylaxis provided: Ondansetron is first line, emerging evidence for NK1 receptor antagonist

If received prophylaxis: Anti-emetic from a different drug class

October 2025